Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Pilot cross-sectional trial of localized transcutaneous magnetic stimulation shows improvement in foot pain secondary to plantar fasciitis (PF), diabetic neuropathy (DN), and chemotherapy neuropathy (CM)
General Neurology
P3 - Poster Session 3 (5:30 PM-6:30 PM)
4-056
To study potential foot pain improvement in patients with PF, DN, and CN with use of TransCutaneous Magnetic Stimulation (TCMS).
The current treatment for foot pain from PF, DN, and CN are less than ideal. Medical therapy leads to adverse side effects.

This is an interim analysis of open label pilot administration of TCMS assessing improvement in foot pain. Patients are enrolled in our neurology clinic via an IRB approved protocol.  Enrollees had constant foot pain from PF, DN, or CN of at least 5 out of 10 in the Numerical Rating Scale (NRS).

 

50 magnetic pulses (1.2 Tesla maximum intensity) were given, 6 seconds apart, to plantar, dorsal and ankle regions of both feet for patients DN and CN and to affected plantar aspect of the foot for PF. NRS was recorded pre- and post-treatment and daily for 7 days then at day 14, 21 and 28. 

 

17 patients are enrolled with a mean age of 55 years (range from 27 years to 71 years), 13 females and 4 males, 14 blacks, 3 whites, 7 with PF, 5 with DN, and 5 with CN. The mean pain score in each individual foot was 6.3 (range 5 to 9) pre-treatment.  Immediately post-treatment, the mean score was 1.68 (range 0-6) and 1-hour post-treatment mean foot pain in each foot individually was 1.5 (range 0-5).  One day post-treatment mean pain in each individual foot was 2.9 (range of 0-7). Response to treatment is lasting at least 7 days and we are following patients up to 28 days.
Of the 17 patients enrolled in this pilot trial, 14 patients with PF, DN, and CN had sustained pain improvement 24-hours post-treatment with a single TCMS treatment with no adverse events. A sham treatment arm and duration of response is planned.
Authors/Disclosures
Ejaz Shamim, MD, MS, MBA, FÂ鶹´«Ã½Ó³»­ (MAPMG)
PRESENTER 		The institution of Dr. Shamim has received research support from Michael J. Fox Foundation.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file